Use of dHACM in the Treatment of Venous Leg Ulcers

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by MiMedx Group, Inc.
Information provided by (Responsible Party):
MiMedx Group, Inc. Identifier:
First received: November 21, 2013
Last updated: November 18, 2014
Last verified: November 2014

November 21, 2013
November 18, 2014
March 2014
March 2015   (final data collection date for primary outcome measure)
Reduction in wound size by ≥40% between both groups [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT02011503 on Archive Site
Percentage of patients in both groups with complete wound healing [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Comparison of Quality of Life as assessed by Short Form 36 (SF-36) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Use of dHACM in the Treatment of Venous Leg Ulcers
A Randomized Controlled Clinical Trial Evaluating The Application Of Dehydrated Human Amnion/ Chorion Membrane (dHACM) Plus Standard Of Care Vs. Standard Of Care Alone In The Treatment Of Venous Leg Ulcers

The overall objective of this study is to evaluate the effectiveness of dehydrated human amnion/ chorion membrane (dHACM) in reducing time to healing in patients with venous leg ulcers (VLUs).

Not Provided
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Leg Ulcer
  • Procedure: Multi-layer compression therapy
    Application of multi-layer compression therapy.
  • Other: Application of dHACM
    Application of dHACM to ulcer.
  • Experimental: dHACM
    Application of multi-layer compression therapy with application of dHACM.
    • Procedure: Multi-layer compression therapy
    • Other: Application of dHACM
  • Control
    Application of multi-layer compression therapy without application of dHACM.
    Intervention: Procedure: Multi-layer compression therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Are at least 18 years old.
  2. Have Ankle Brachial Pressure Index (ABI) > 0.75. (Calculations will be made using measurements from both posterior tibial and dorsalis pedis arteries as well as both arms).
  3. Have venous leg ulcer extending through the full thickness of the skin but not down to muscle, tendon or bone. The largest ulcer will be designated the index ulcer and the only one included in the study. If other ulcerations are present on the same extremity, these must be more than 2 cm apart from the index ulcer.
  4. Have venous insufficiency confirmed by duplex ultrasound examination for valvular or venous incompetence.
  5. Have study ulcer (i.e. current episode of ulceration) that has been present for at least one month prior to the initial screening visit. Note: The patient is excluded if ulcer has undergone 12 months of continuous high strength compression therapy over its duration.
  6. Have study ulcer with a minimum of 2 cm2 and a maximum of 25 cm2 at the randomization visit.
  7. The target ulcer has been treated with compression therapy for at least 14 days prior to randomization.
  8. Ulcer has a clean, granulating base with minimal adherent slough at the randomization visit.
  9. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  10. Patient understands and is willing to comply with weekly visits and the follow-up regimen.
  11. Patient has read and signed the Institutional Review Board (IRB) approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria:

  1. Study ulcer(s) deemed by the investigator to be caused by a medical condition other than venous insufficiency.
  2. Study ulcer exhibits clinical signs and symptoms of infection.
  3. Study ulcer, in the opinion of the investigator, is suspicious for cancer should undergo an ulcer biopsy to rule out a carcinoma.
  4. Patients with a history of more than two weeks treatment with immunosuppressants (including systemic corticosteroids), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 30 days of initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  5. Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
  6. History of radiation at the ulcer site.
  7. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  8. Study ulcer has been previously treated with tissue engineered materials (e.g. Apligraf® or Dermagraft®) or other scaffold materials (e.g. Oasis, Meristem) within the last 30 days
  9. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the course of the trial.
  10. Patients who are unable to understand the aims and objectives of the trial.
  11. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  12. New York Heard Association (NYHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: Class III: Symptoms with moderate exertion; Class IV: Symptoms at rest.
  13. Ulcers on the dorsum of the foot or with more than 50% of the ulcer below the malleolus are excluded.
  14. Pregnant or breast feeding.
  15. Currently taking medications which, in the opinion of the treating physician, could affect graft incorporation.
  16. Allergic to gentamicin and/or streptomycin
  17. Known allergy to the components of the multi-layer compression bandaging, or who cannot tolerate multi-layer compression therapy.
  18. History of drug or alcohol abuse within 6 months of screening.
18 Years and older
Contact: Richard Odom, DPM
United States
MiMedx Group, Inc.
MiMedx Group, Inc.
Not Provided
Principal Investigator: Richard Odom, DPM Veteran's Administration
MiMedx Group, Inc.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP